GlassScriptPhysician profile
Sharla Carroll
NPI 1689739278
$3,627.73
in general payments reported to CMS, 2019-2025
31 companies · $768 in 2025
The $768 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $462 · 2022: $894 · 2023: $763 · 2024: $741 · 2025: $768.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,272.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,271.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $857.72 | 2021-2025 | Farxiga, Breztri, Airsupra |
| Lilly USA, LLC | $412.44 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $365.71 | 2021-2025 | |
| Astellas Pharma US INC | $342.83 | 2021-2025 | Veozah, Myrbetriq |
| Merck Sharp & Dohme LLC | $159.88 | 2021-2023 | Belsomra, Verquvo, Steglatro |
| Novo Nordisk INC | $154.01 | 2021-2025 | Ozempic, Rybelsus |
| Abbott Laboratories | $152.47 | 2021-2025 | Freestyle Libre |
| Bayer Healthcare Pharmaceuticals INC. | $134.91 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $110.58 | 2021-2023 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.41 | 2022-2025 | Caplyta |
| Glaxosmithkline, LLC. | $96.52 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Jazz Pharmaceuticals INC. | $89.03 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $84.89 | 2021-2025 | Trintellix |
| Phathom Pharmaceuticals, INC. | $78.82 | 2024-2025 | Voquezna |
| Biohaven Pharmaceutical Holding Company LTD. | $56.74 | 2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $56.16 | 2024-2025 | Gemtesa |
| Otsuka America Pharmaceutical, INC. | $52.30 | 2022-2023 | Rexulti |
| Soleno Therapeutics, INC. | $46.06 | 2025 | Vykat Xr |
| Teva Pharmaceuticals USA, INC. | $33.57 | 2023 | Austedo Xr |
| Corcept Therapeutics | $32.37 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $28.81 | 2022 | |
| Axsome Therapeutics, INC. | $21.37 | 2025 | Auvelity |
| Biohaven Pharmaceuticals, INC. | $20.49 | 2021 | |
| Mylan Specialty L.P. | $19.22 | 2024 | Yupelri |
| Pfizer INC. | $18.75 | 2025 | |
| Medtronic, INC. | $18.21 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $17.37 | 2023 | |
| Aimmune Therapeutics, INC. | $16.64 | 2025 | Zenpep |
| Exact Sciences Corporation | $15.45 | 2025 | Cologuard Collection Kit |
| Janssen Pharmaceuticals, INC | $12.94 | 2023 | Xarelto |
| Biogen, INC. | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sharla Carroll listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.